Fluoropyrimidine
Phase 3Small molecule
RocheFluoropyrimidine is one of 137 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.
6
Indications
11
Total Trials
3
Active Trials
136
Competitors
Pipeline
Status by Indication[3][1]
Indication
Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical
Active, not recruiting
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Fluoropyrimidine
RochePhase 3
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Ketalar
AAultman Health Foundation
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer3 trials
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
Unknown status·—·Phase 3·NCT04188145·400 enrolled
Gastric Cancer1 trial
Adenocarcinoma1 trial
4 more indications
Effectiveness1 trial
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluoropyrimidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]